Consider the following medical report that includes the patient's historical health records. Use it to predict the disease that the patient is high likely exposed to. 

 Medical Report: allergies: patient recorded as having no known allergies to drugs attending: chief complaint: headache major surgical or invasive procedure: none history of present illness: 70 yo rh female with ho htn, dmii, afib recently admitted to stroke service at for left mca infarct and started on coumadin not presents with ich in infarction site. original stroke occured on asa. patient was hospitalized from after presenting with aphasia and right sided weakness. she had h/o paf and cth showed large hypodensity on left side on and repeat head ct showed evolution of infarct with minimal hemorrhage on day of discharge. patient started on heparin gtt and transitioned to coumadin. she was sent to hospital for rehab and was doing well but complaining of ha starting 10 days ago. patient worked well with pt but son noted that 4 days ago she vomited during a pt session. her inrs were difficult to get into therapeutic range but peak inr was 5 days ago at 5.8. coumadin was stopped and restarted this week. last inr documented in osh records is inr 4 on and coumadin held again. per son, patient's inr was 2 yesterday and she was given small dose coumadin. inr now is 1.8. per son, patient is at her baseline since stroke, maybe more confused and agitated this week. she otherwise has been well, no fevers, uri symptoms, diarrhea, cp, sob, ab pain. past medical history: hypertension junctional bradycardia on nodal agents, tachyarrhythmia off, s/p pacemaker paroxysmal atrial fibrillation - per dr. notes, she had declined warfarin and was supposed to be taking an aspirin daily, although it's not clear that this was the case. htn dm2 diastolic hf recent cellulitis of rle, treating with amp/gent till social history: russian-speaking. quit smoking 11 months ago, before which she had smoked ppd for many years. no etoh or illicits per her son. family history: father died at stroke at 74. physical exam: vitals: t: afp: 68 r: 16 bp: 153-161/60-68 sao2: 100% ra general: awake, alert, agitated. heent: nc/at, no scleral icterus noted, mmm, no lesions noted in oropharynx neck: supple, no carotid bruits appreciated. no nuchal rigidity pulmonary: lungs cta bilaterally without r/r/w cardiac: irreg irreg, nl. s1s2, no m/r/g noted abdomen: soft, nt/nd, normoactive bowel sounds, no masses or organomegaly noted. extremities: no c/c/e bilaterally, 2+ radial, dp pulses bilaterally. skin: no rashes or lesions noted. neurologic: -mental status: awake, agitated, does not follow ml commands but points to son. inattentive to exam -cranial nerves: i: olfaction not tested. ii: perrl 3 to 1mm and brisk. vff to threat bilat. funduscopic exam not possible due to lack of cooperation. iii, iv, vi: eomi. v: good corneals. vii: no facial droop, facial musculature symmetric. viii: hearing not testable. ix, x: strong gag. : 5/5 strength in trapezii and scm bilaterally. xii: tongue protrusion not tested. -motor/: has right near falccid arm with some minimal distal finger ext spont and distal wd to nox stim. left arm and leg moving ag spont. right leg wd but no ag to noxious stim. seems to localize pain. -dtrs: tri pat ach l 1 1 1 1 tr r 1 1 1 1 tr plantar response was extensor on the right, flexor on the left. -coordination: reaches for obj on left with no tremor. -gait: not testable. pertinent results: 07:00am wbc-6.8 rbc-3.97* hgb-11.0* hct-33.7* mcv-85 mch-27.8 mchc-32.8 rdw-14.0 plt ct-311 pt-16.1* ptt-26.6 inr(pt)-1.4* glucose-182* urean-12 creat-1.1 na-139 k-3.3 cl-98 hco3-29 angap-15 calcium-9.9 phos-4.4 mg-1.8 admission labs: 138 98 15 agap=17 ------------<138 4.9 28 1.1 wbc 8.6 hgb 10.8 plts 293 hct 33.3 n:60.0 l:31.8 m:5.5 e:2.5 bas:0.3 pt: 18.1 ptt: 26.7 inr: 1.7 ct head w/o contrast 3:39 pm in comparison with the prior study, there is evidence of hemorrhagic transformation on the previously described area of ischemia in the left mca vascular territory. the area of hemorrhage is demonstrated as a hyperdense heterogeneous area, effacement of the sulci, and midline shifting is also detected with approximately 4.4 mm of midline shifting to the right. the perimesencephalic cisterns are patent without evidence of uncal herniation. increase in the pattern of vasogenic edema surrounding the hemorrhagic area as well as effacement of the left lateral ventricle. the core of the hematoma measures approximately 2.9 x 5.3 cm at the level of the left temporal lobe and insula. impression: large hemorrhagic transformation on a prior ischemic area involving the left mca vascular territory, associated with vasogenic edema, effacement of the sulci, and midline shifting as described above. ct head w/o contrast 10:22 am findings: again identified is a hemorrhagic infarction of the left middle cerebral artery territory and associated vasogenic edema. there is no new hemorrhage identified. there is no change in appearance of effacement of sulci or increase in the degree of midline shift. impression: large left mca territory hemorrhage, with no significant change in edema or midline shift. brief hospital course: 70 yo rh female with ho htn, dmii, afib recently admitted to stroke service at for left mca infarct and started on coumadin now presents with large ich in infarction site. 1) left mca hemorrhagic transformation- likely etiology was supratherapeutic levels of coumadin at outside hospital, reported by son to have as high as . she reported headache for approximately 10 days preceding her current presentation. ct on admission revealed hematoma measuring approximately 2.9 x 5.3 cm at level of temporal lobe and insula compressing the left lateral vent with 4-5 mm midline shift. her examination at presentation was slightly improved from her last examination at time of discharge- this is likely because the hemorrhage was contained within the prior infarct region. patient was given 2 units ffp and 1 dose vit k far and admitted to the neuro icu for close observation and blood pressure control. she was continued on keppra 500mg for seizure prophylaxis. interval ct scan did not reveal worsening of the hemorrhage or midline shift. 2) lower extremity cellulitis and enterococcus bacteremia: she completed her 4-week course of ampicillin and gentamicin on and her picc line should be discontinued. in hospital there were no signs of le erythema, edema or tenderness. she was transferred the floor where she was stable. on , because of the concern re persistent aphasia, she had a repeat nchct which was unchanged. her exam at discharge: global aphasia (mute but mouthing, inconsistently follows basic commands), r facial droop and hemiparesis with rue plegia and triple flexious response to noxious stim of rle, r upgoing plantar response, l-sided strength full. she was hypertensive and hyperglycemic so her antihypertensives (lisinopril initially 20 but decreased to 10 due to bp dip, metoprolol 37.5 tid, lasix 40) and metformin were restarted. she is also on atorvastatin. her keppra was discontinued. we recommend that she be restarted on her coumadin 14 days after the hemorrhage which occurred , without heparin bridge, but this should be done at conservative doses and with frequent inr monitoring. she is being transferred back to . she is also on hep 5000 u sc tid for dvt prophylaxis while not anticoagulated. medications on admission: ampicillin 2 grams iv q4h gentamycin 60 mg iv q8h metformin 850 magnesium 30 ml qday biscodyl 10 mg pr qd zofran 4 mg qday lisinopril 5 mg qpm nitroglycerine oint furosemide 20 mg qday warfarin 1 mg qday riss simvistatin 40 mg qday lansprazole 30 mg qday colace 100 mg miconazole ferrous sulfate tylenol prn senna discharge medications: 1. docusate sodium 100 mg capsule : one (1) capsule po bid (2 times a day). 2. metoprolol tartrate 5 mg/5 ml solution : 2.5 mg, repeat x 1 mg intravenous q4h (every 4 hours) as needed for sbp > 160. 3. lansoprazole 30 mg tablet,rapid dissolve, dr : one (1) tablet,rapid dissolve, dr daily (daily). 4. senna 8.6 mg tablet : one (1) tablet po bid (2 times a day) as needed for constipation. 5. atorvastatin 40 mg tablet : one (1) tablet po daily (daily). 6. insulin regular human 100 unit/ml solution : scale scale injection asdir (as directed). 7. metoprolol tartrate 25 mg tablet : 1.5 tablets po tid (3 times a day). 8. furosemide 40 mg tablet : one (1) tablet po daily (daily). 9. metformin 850 mg tablet : one (1) tablet po bid (2 times a day). 10. lisinopril 5 mg tablet : two (2) tablet po daily (daily). 11. bisacodyl 5 mg tablet, delayed release (e.c.) : two (2) tablet, delayed release (e.c.) po daily (daily) as needed. 12. magnesium hydroxide 400 mg/5 ml suspension : thirty (30) ml po q6h (every 6 hours) as needed. 13. heparin (porcine) 5,000 unit/ml solution : 5000 (5000) units injection tid (3 times a day). discharge disposition: extended care facility: - discharge diagnosis: hemorrhagic conversion of recent l mca ischemic stroke in the context of supratherapeutic inr discharge condition: neurologically stable, globally aphasic, r hemiparesis discharge instructions: you have had bleeding in the area of your previous stroke, in the setting of a very high inr. you should restart your coumdadin 14 days after this bleeding, with very conservative management and lower dose than previous, and make sure to have your inr monitored frequently. please call your primary care physician or present to the nearest emergency department if you have any worsening of your symptoms or new concerning symptoms. followup instructions: clinic: dr. date/time: 10:00 phone: radiology date/time: 1:00 phone: , np date/time: 2:40 phone: md, procedure: transfusion of other serum diagnoses: abnormal coagulation profile congestive heart failure, unspecified unspecified essential hypertension diabetes mellitus without mention of complication, type ii or unspecified type, not stated as uncontrolled atrial fibrillation intracerebral hemorrhage cellulitis and abscess of leg, except foot bacteremia cerebral edema long-term (current) use of anticoagulants streptococcus infection in conditions classified elsewhere and of unspecified site, streptococcus, group d [enterococcus] anticoagulants causing adverse effects in therapeutic use chronic diastolic heart failure 

Answer: The patient is high likely exposed to